Bharat Immunologicals & Biologicals (BOM:524663) Net Income From Continuing Operations : ₹-180.65 Mil (TTM As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Bharat Immunologicals & Biologicals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Bharat Immunologicals & Biologicals's net income from continuing operations for the three months ended in Sep. 2023 was ₹-49.18 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2023 was ₹-180.65 Mil.

Bharat Immunologicals & Biologicals Net Income From Continuing Operations Historical Data

The historical data trend for Bharat Immunologicals & Biologicals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bharat Immunologicals & Biologicals Net Income From Continuing Operations Chart

Bharat Immunologicals & Biologicals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-73.74

-142.03

-242.08

-96.87

-222.68

Bharat Immunologicals & Biologicals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-30.83	-46.84	-38.76	-45.87	-49.18

Bharat Immunologicals & Biologicals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-180.65 Mil.

Bharat Immunologicals & Biologicals (BOM:524663) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bharat Immunologicals & Biologicals Corp Ltd (BOM:524663) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203

Website

http://www.bibcol.sciencecentral.in

Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

Bharat Immunologicals & Biologicals (BOM:524663) Headlines

No Headlines